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Type III 3-methylglutaconic aciduria (MGA) (MIM 258501) is a neuro-ophthalmologic syndrome that consists of
early-onset bilateral optic atrophy and later-onset spasticity, extrapyramidal dysfunction, and cognitive deficit.
Urinary excretion of 3-methylglutaconic acid and of 3-methylglutaric acid is increased. The disorder has been
reported in ∼40 patients of Iraqi Jewish origin, allowing the mapping of the disease to chromosome 19q13.2-q13.3,
by linkage analysis. To isolate the causative gene, OPA3, we sequenced four genes within the critical interval and
identified, in the intronic sequence of a gene corresponding to cDNA clone FLJ22187, a point mutation that
segregated with the type III MGA phenotype. The FLJ22187-cDNA clone, which we identified as the OPA3 gene,
consists of two exons and encodes a peptide of 179 amino acid residues. Northern blot analysis revealed a primary
transcript of ∼5.0 kb that was ubiquitously expressed, most prominently in skeletal muscle and kidney. Within the
brain, the cerebral cortex, the medulla, the cerebellum, and the frontal lobe, compared to other parts of the brain,
had slightly increased expression. The intronic GrC mutation abolished mRNA expression in fibroblasts from
affected patients and was detected in 8 of 85 anonymous Israeli individuals of Iraqi Jewish origin. Milder mutations
in OPA3 should be sought in patients with optic atrophy with later onset, even in the absence of additional
neurological abnormalities.
Introduction
3-Methylglutaconic aciduria (MGA) has been divided into
four different disease categories (Gibson et al. 1993). Type
IMGA, characterized bymild neurological disease, results
from deficiency of 3-methylglutaconyl-CoA hydratase in
the leucine-oxidation pathway. Type II MGA, or Barth
syndrome, is an X-linked disorder that consists of dilated
cardiomyopathy, short stature, and neutropenia and that
results from mutations in the tafazzin gene (G4.5) (Bione
et al. 1996). Type III MGA, or Costeff optic-atrophy syn-
drome, occurs in Iraqi Jews as a relatively homogeneous
neuro-ophthalmologic disorder. In contrast, type IVMGA
is extremely heterogeneous, with moderate-to-severe neu-
rological disease, sometimes associated with cardiac, oph-
thalmic, hepatic, and renal symptoms.
The distinctive phenotype of type III MGA (MIM
258501) and its occurrence in members of a genetic
isolate have led to the mapping of the responsible gene
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to chromosome 19q13.2-q13.3 (Nystuen et al. 1997).
Characteristic clinical manifestations include early-on-
set bilateral optic atrophy and later-onset spasticity, ex-
trapyramidal dysfunction, ataxia, and cognitive deficit
(Costeff et al. 1989, 1993). Urinary excretion of 3-meth-
ylglutaconic acid and of 3-methylglutaric acid is in-
creased to variable degrees in all patients and is con-
sidered a hallmark of the disease, allowing diagnosis as
early as 1 year of age, in infants with optic atrophy.
Life span of affected individuals appears normal, and
affected adults in the 4th decade of life have been re-
ported (Elpeleg et al. 1994). Neither the basic defect in
type III MGA nor the gene causing type III MGA has
been identified. In this study, we sought candidate genes
within the minimal disease region (between markers
D19S412 and D19S918), isolated the gene responsible
for type III MGA, and determined its tissue-expression
pattern; we also identified the founder mutation causing
the disease in the Iraqi Jewish isolate that we studied,
developed a screening assay for the mutation, and es-
timated its population frequency.
Subjects and Methods
Subjects
DNA was available from 10 patients, 7 obligatory
heterozygotes, and 4 healthy siblings of eight Iraqi Jew-
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Figure 1 Demonstration of founder mutation in OPA3 in Iraqi Jewish family. a, Sequence of intron 1/exon 2 boundary of OPA3, in
normal control, affected patient, and three family members. The GrC mutation was present in the homozygous state in the daughter and in
the heterozygous state in the mother and the father. b, Gel electrophoresis of PCR-amplification products cut with RsaI. A 540-bp fragment in
the region of interest was amplified by primers R2 and MDP, the latter of which was specifically designed to introduce an additional RsaI
cleavage site into the product formed using the mutant sequence as template. Treatment with RsaI produced a 280-bp band in all patients; in
addition, a 180-bp fragment was visible in normal individuals, a 161-bp fragment was apparent in affected patients, and the 180-bp and 161-
bp bands were both present for obligate heterozygotes.
ish families. All the patients exhibited optic atrophy, a
movement disorder, and increased urinary excretion of
3-methylglutaconic acid and of 3-methylglutaric acid.
Informed consent was obtained from all patients in these
studies.
DNA of 75 anonymous individuals of Iraqi Jewish
origin was purchased from the National Laboratory
for the Genetics of Israeli Populations. An additional
10 samples from anonymous Iraqi Jews were obtained
from the Israeli familial-Mediterranean-fever screening
program. DNA samples of North Americans were ob-
tained from patients with other disorders, after written
informed consent was obtained.
Sequencing and Sequence Analyses
The sequences ofNOVA2, FLJ20084, FLJ22187, and
SYMPLEKIN were determined using genomic DNA ob-
tained from cultured fibroblasts from three patients with
type III MGA who originated from different families.
DNA of other family members and of anonymous con-
trols was obtained from peripheral leukocytes.
PCR amplification of each exon of the FLJ22187
clone was performed by amplifying 200–400 ng of ge-
nomic DNA by use of Ready-To-Go PCR Beads (Amer-
sham Pharmacia Biotech) with 10 pmol each primer, in
a total volume of 25 ml. Cycling parameters included
initial denaturation at 96C for 4 min; followed by cycles
of denaturation at 94C for 1 min, annealing at 58C
for 45 s, and extension at 70C for 90 s; and concluding
with elongation at 72C for 10 min. The PCR products
were electrophoresed in 1% agarose and were stained
with ethidium bromide. Oligonucleotide primers were
designed using the sequence of chromosome 19 and are
as follows: F1 (5′-CGTACATACGTACTGACGCA-3′),
R1 (5′-TAAGCAACCACCTGACAGG-3′), F2 (5′-TCC-
CAGAGCGCAGCCTGAC-3′), and R2 (5′-GCCAAGT-
TGCATCAAGATCCT-3)′.
Automated sequencing was performed on a Beckman
CEQ 2000, by the CEQ Dye Terminator Cycle Sequenc-
ing kit, according to the manufacturer’s protocol (Beck-
man Coulter). BLAST analysis was performed for se-
quence-homology searches, available through the Na-
tional Center for Biotechnology Information. Analysis of
the amino acid sequence was performed by the PSORT
software.
Mutation Screening
A 540-bp fragment containing two RsaI restriction
sites was created using primer R2 and the “mutation-
detection primer” (MDP [5′-GACCCCTCTCTTCCCC-
CGTA-3′]). Incubation of the normal fragment at 37C
for 3 h with RsaI resulted in its cleavage into three frag-
ments (of 280 bp, 180 bp, and 80 bp), which could be
separated on a 2.5% agarose gel. Incubation of the frag-
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Figure 2 Northern blot analyses by 619-bp probe to human OPA3 cDNA. a, Probe hybridized to 5.0-kb band and secondary 8.0-kb
band in all tissues tested. Expression appeared greatest in skeletal muscle and kidney. The lower panel shows the band for b-actin, which served
as a control for RNA loading. b, Same bands on human multiple-tissue northern blot, demonstrating expression in all parts of brain. c, 5.0-
kb and 8.0-kb bands of RNA from normal fibroblasts (N-1 and N-2), which hybridized with OPA3-cDNA probe, whereas no bands appeared
on use of RNA from fibroblasts from one Iraqi Jewish patient (Pt.).
ment created by amplification of the mutant DNA
yielded four fragments (of 280 bp, 161 bp, 80 bp, and
19 bp). The mutation could be detected by the appear-
ance of a 161-bp band instead of the 180-bp band.
Northern Blot Analysis
Multiple-tissue northern filters, loaded with poly(A)
RNA (2 mg/lane) derived from a number of human tis-
sues, were purchased from Clontech. In addition, we
isolated total RNA (20 mg) from cultured fibroblasts by
use of Trizol reagent (Life Technologies). The RNA was
separated on a 1.2% agarose/3% formaldehyde gel and
was blotted onto a Nytran nylon membrane (Schleicher
and Schuell) in the presence of 20# SSC. Blots were
prehybridized and then were hybridized with Express
Hyb solution (Clontech) at 68C. The probe was com-
posed of human OPA3 cDNA, was 619-bp long, was
random-primer labeled with a-[32P]-dCTP (DuPont/New
England Nuclear), and was prepared by PCR amplifi-
cation of normal cDNA, by primers CF1 (5′-GGTTGC-
GCGTGCCCTGTGA-3′) and CB1 (5′-ACGTTAGGTA-
CATAGGCCATG-3′). The same set of filters was also
probed with b-actin.
Results
The gene for type IIIMGA,OPA3,was previously shown,
through linkage studies, to reside between polymorphic
markers D19S918 and D19S412. Of the many genes lo-
cated within this region, we chose four for intensive in-
vestigation. Two genes—NOVA2 (neuro-oncologic ven-
tral antigen 2) and SPK (or SYMPLEKIN, encoding hun-
tingtin interacting protein I)—were chosen owing to their
expression in brain and to their putative connections
with the clinical manifestations of the disease. Exhaus-
tive sequencing, however, revealed nomutations in either
gene. Two other clones—FLJ20084 and FLJ22187—
were studied, specifically because their function was to-
tally unknown. Sequencing of FLJ20084 revealed no
mutations; however, the FLJ22187 clone could not be
amplified from the cDNA of patients with type III MGA,
although control cDNA yielded the expected 619-bp
band (data not shown). We next elucidated the genomic
structure of the FLJ22187 clone, by BLAST sequence
analysis. The complete gene has two exons: exon 1 is
located in clone CTB-124I16 (GenBank accession num-
ber GI:10799401), and exon 2 is located in cosmid
R32889 (GenBank accession number GI:4079613). This
information enabled us to design primers for the coding
region of OPA3 in genomic DNA.
These primers were employed to determine theOPA3
mutation causing type III MGA in our cohort of pa-
tients. We sequenced OPA3 coding exons, as well as
their adjacent splice-site regions, using genomic DNA
of three affected individuals. Each patient exhibited a
homozygous GrC change at the 1 position of intron
1 in the 3′ (acceptor) splice site. This information per-
mitted the development, by use of genomic DNA, of a
restriction-enzyme–based assay of the mutation. We de-
signed a PCR primer, called “MDP,” containing a spe-
cific nucleotide mismatch 2 bases upstream of the GrC
mutation, so that the amplified fragment would contain
an additional RsaI restriction site in the mutated allele
but not in the normal allele. Amplification and cleavage
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Figure 3 OPA3 gene and protein sequence. Nucleotide 1 cor-
responds to nucleotide 22 of FLJ22187. The first three nucleotides,
shown in boldface, comprise the nearest stop codon 5′ to the open
reading frame. The arrow after nucleotide 142 denotes the border
between exons 1 and 2.
with RsaI revealed that the GrC mutation segregated
with type III MGA in 10 affected individuals, 7 obligate
heterozygotes, and 4 healthy siblings. An example is
presented in figure 1. The mutation was also found in
8 of 85 anonymous Israelis of Iraqi Jewish origin but
in 0 of 55 North Americans.
Northern blot analysis by a 619-bp OPA3-cDNA
probe revealed 5.0-kb and 8.0-kb messages that were
ubiquitously expressed, most prominently in skeletal
muscle and kidney (fig. 2a). Within the brain, the ce-
rebral cortex, the medulla, the cerebellum, and the fron-
tal lobe, compared with other parts of the brain, had
slightly increased expression (fig. 2b). The message was
present in normal cultured fibroblasts but was not pre-
sent in fibroblasts obtained from an affected individual
(fig. 2c).
To confirm the open reading frame ofOPA3, we per-
formed an expressed-sequence–tag search, sequenced
the region 5′ to FLJ22187, and located a stop codon
(tga) at position 150 with respect to the ATG trans-
lation start site (fig. 3). OPA3 consists of this 5′ UTR,
an open reading frame encoding 179 amino acids, and
1970 nucleotides of 3′ untranslated sequence (fig. 3).
The protein product is predicted to be a 20-kD peptide
and to consist of 61% a helix, 12% extended strand,
4% b turn, and 22% random coil. The sequence con-
tains a mitochondrial targeting peptide, NRIKE, at
amino acid residues 25–29 and is predicted, with a
probability of .87, to be exported to the mitochondrion.
The gene product’s first 114 amino acids are 54% iden-
tical to those of Drosophila melanogaster cytochrome
B heme and 28% identical to those of a hypothetical
coiled-coil protein of Schizosaccharomyces pombe. A
conserved motif of 22 amino acids exists among the
human, the D. melanogaster, and the yeast homologues
of OPA3 (fig. 4).
Discussion
Metabolic diseases characterized byMGAhave confused
students for decades. Of the four categories of MGA, the
most frustrating to study remains type IV, a category in
which patients present with phenotypes that have not yet
been characterized by a primary enzymatic or molecular
defect; some instances of this type may eventually be as-
similated into other existing disease categories, including
the other three types of MGA. The first step toward re-
vealing the pathophysiology of these three types has been
made—that is, they have all had their causative genes
isolated. Type I MGA results from absence of 3-methyl-
glutaconyl-CoA hydratase activity, type II MGA results
from mutations in tafazzin, and we now report the se-
quence, genomic organization, and mRNA product of
OPA3, the gene responsible for type III MGA. The prom-
inent expression of OPA3 mRNA in the cerebral cortex,
the medulla, the cerebellum, and the frontal lobe is con-
sistent with the spasticity and the ataxia observed in pa-
tients with type III MGA, who lack a functional gene
product.
The product’s function remains unknown, and ho-
mologies to proteins of other species have not been il-
lustrative; however, several findings suggest that the
OPA3 protein plays some role in mitochondrial pro-
cesses:
1. OPA3 contains a mitochondrial targeting signal. Al-
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Figure 4 Conserved motif of 22 amino acids within human, D. melanogaster, and yeast homologues of OPA3. Numbers indicate the
position of the first amino acid in the conserved region; letters in boldface indicate amino acids conserved among all three species.
though supporting evidence from cell-biological studies
would be required, the putative mitochondrial localiza-
tion of OPA3 would be consistent with the optic atrophy
observed in patients with type III MGA. Individuals with
mitochondrial disorders also exhibit optic atrophy; spe-
cifically, autosomal dominant optic atrophy results from
mutations in OPA1 (which encodes a dynamin-related
mitochondrial protein), and Leber hereditary optic at-
rophy (variably associated with a movement disorder)
results from mtDNA mutations (Riordan-Eva and Har-
ding 1995; Delettre et al. 2000). Notably, digitonin-per-
meabilized fibroblasts from two patients with type III
MGA exhibited a 50% reduction in ATP production and
a fourfold increase in lactate:pyruvate ratio (Wanders
et al. 1992; A. Saada and O. Elpeleg, unpublished data),
both of which are indications of impaired mitochondrial
function.
2. The presence of increased MGA itself suggests mi-
tochondrial involvement. Fibroblasts from patients with
type II MGA contain a markedly reduced amount of car-
diolipin, a phospholipid found exclusively in the inner
mitochondrial membrane and required for optimal func-
tion of respiratory-chain enzymes (Vreken et al. 2000).
Mitochondrial respiratory-chain defects have been re-
ported in several patients with type IV MGA (Ibel et al.
1993; Besley et al. 1995), and MGA has been reported
in patients with other mitochondrial respiratory-chainde-
fects, including mtDNA-depletion syndromes, mtDNA
deletions, and ATP-synthase deficiency (Gibson et al.
1992; Holme et al. 1992; Scaglia et al. 2001). The link
between MGA and mitochondrial respiratory-chain de-
fects likely involves the mevalonate shunt; this pathway
produces 3-methylglutaconyl-CoA from mevalonate via
dimethylallyl pyrophosphate (Edmond and Popjak 1974),
an intermediate in the synthesis of cholesterol and polyi-
soprenoids, such as ubiquinone. It has been speculated
that defective ubiquinone biosynthesis could lead to in-
creased levels of precursors (e.g., mevalonate) in the path-
way, thereby increasing synthesis of 3-methylglutaconic
acid (Kelley and Kratz 1995). We have seen no beneficial
effect, on administration of an active form of ubiquinone,
coenzyme Q10, to three patients with type III MGA (Cos-
teff et al. 1998).
3. The carboxy terminal motif, SKK, of the OPA3
gene product somewhat resembles a peroxisomal tar-
geting signal (Gould et al. 1989), and there is precedent
for the existence of mixed mitochondrial/peroxisomal
proteins. In particular, 3-hydroxy-3-methylglutaryl-CoA
lyase has both a mitochondrial targeting signal and a
peroxisomal targeting motif and resides both in mito-
chondria and in peroxisomes (Ashmarina et al. 1994).
The SKK motif found in the OPA3-gene product, how-
ever, has been specifically shown to target proteins to
the cytoplasm (Gould et al. 1989), mitigating against a
dual localization for OPA3.
Whatever the role played by the OPA3-gene product
may be, a specific GrC intron 1 acceptor splice-site
mutation causes the type III MGA phenotype in the
patients whom we studied. This base substitution vio-
lates the GT-AG rule, changing the splice-junction score
from 86.9% to 70.9% (Shapiro and Senepathy 1987).
The resulting lack of mRNA expression manifests as the
absence of an OPA3 band on a northern blotting of
fibroblasts from affected patients and as an inability to
amplify the FLJ22187 clone by use of patients’ cDNA.
The complete absence of an OPA3 transcript is asso-
ciated with early-onset optic atrophy and a movement
disorder of variable severity, which begins in early ad-
olescence. Milder mutations in OPA3, however, may
cause optic atrophy with onset later in life and perhaps
without additional neurological abnormalities.
The GrC splice-site mutation in OPA3 segregated
with type III MGA in the Iraqi Jewish families that we
studied and was also detected in 8 of 85 anonymous
individuals of Iraqi Jewish origin. This suggests that the
mutation has a long history within this genetic isolate
—which represents the original Middle-Eastern Jewish
gene pool, derived from ∼120,000 Jews whowere exiled
to Babylon in 586 B.C., after the destruction of the First
Temple and of Jerusalem. The relative isolation of this
population, for 2,500 years, resulted in a high (3.3%)
carrier rate for the common mutation in the factor XI
gene (Shpilberg et al. 1995), in a remarkably high (39%)
carrier rate for the common mutation in theMEFV gene
(which causes familial Mediterranean fever [Stoffman
et al. 2000]), and in a frequency of 5% for the auto-
somal dominant disorder pseudocholinesterase defi-
ciency (Zlotogora et al. 2000). According to the Israeli
Central Bureau of Statistics, the number of Iraqi Jews
living in Israel in 1998 was ∼253,200. With a carrier
frequency of ∼1/10 for the founder mutation in OPA3,
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the predicted number of patients affected with type III
MGA would be 633. The actual number is lower, prob-
ably because the gene pool has been diluted. Since 1948,
127,000 Iraqi Jews have immigrated to Israel, and large
communities exist in India, in the United Kingdom, in
Montreal, and in Australia. It would be of great interest
to determine the frequency of the OPA3 splice-site mu-
tation and its associated disorder in these genetic iso-
lates as well. It will also be of critical importance to
identify (1) other patients with type III MGA and (2)
other OPA3 mutations, to determine the phenotypic
spectrum of this disorder.
Acknowledgments
Y.A. is a Howard Hughes Medical Institute Physician Post-
doctoral Fellow. The authors thank Y. Shinar for the anony-
mous DNA samples and Diana L. Fitzpatrick for her technical
assistance.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for human
OPA3 [FLJ22187] [accession number GI:14761409], clone
CTB-124I16 [accession number GI:10799401], cosmid
R32889 [accession number GI:4079613], S. pombe hypo-
thetical coiled-coil protein [accession number GI:6723925],
and D. melanogaster homologue [accession number GI:
7301068])
National Laboratory for the Genetics of Israeli Populations,
http://www.tau.ac.il/medicine/NLGIP/nlgip.htm
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for type IIIMGA [MIM258501])
PSORT WWW Server, http://psort.nibb.ac.jp/
References
Ashmarina LI, Rusnak N, Miziorko HM, Mitchell GA (1994)
3-Hydroxy-3-methylglutaryl-CoA lyase is present in mouse
and human liver peroxisomes. J Biol Chem269:31929–31932
Besley GT, Lendon M, Broadhead DM, Till J, Heptinstall LE,
Phillips B (1995) Mitochondrial complex deficiencies in a
male with cardiomyopathy and 3-methylglutaconic aciduria.
J Inherit Metab Dis 18:221–223
Bione S, D’Adamo P, Maestrini E, Gedeon AK, Bolhuis P-A,
Toniolo D (1996) A novel X-linked gene, G4.5. is respon-
sible for Barth syndrome. Nat Genet 12:385–389
Costeff H, Apter N, Elpeleg ON, Prialnic M, Bohles HJ (1998)
Ineffectiveness of oral coenzyme Q10 supplementation in 3-
methylglutaconic aciduria, type 3. Brain Dev 20:33–35
Costeff H, Elpeleg O, Apter N, Divry P, Gadoth N (1993) 3-
Methylglutaconic aciduria in “optic atrophy plus.” Ann
Neurol 33:103–104
Costeff H, Gadoth N, Apter N, Prialnic M, Savir H (1989) A
familial syndrome of infantile optic atrophy, movement dis-
order, and spastic paraplegia. Neurology 39:595–597
Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C,
Belenguer P, Pellouin L, Grosgeorge J, Turc-Carel C, Perret
E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun
B, Kaplan J, Hamel CP (2000) Nuclear gene OPA1, encod-
ing a mitochondrial dynamin-related protein, is mutated in
dominant optic atrophy. Nat Genet 26:207–210
Edmond J, Popjak G (1974) Transfer of carbon atoms from
mevalonate to n-fatty acids. J Biol Chem 249:66–71
Elpeleg ON, Costeff H, Joseph A, Shental I, Weitz R, Gibson
KM (1994) 3-Methylglutaconic aciduria in the Iraqi Jewish
‘optic atrophy plus’ (Costeff) syndrome. Dev Med Child
Neurol 36:167–172
Gibson KM, Bennett MJ, Mize CE, Jakobs C, Rotig A, Mun-
nich A, Lichter-Konecki U, Trefz FK (1992) 3-Methylglu-
taconic aciduria associated with Pearson syndrome and res-
piratory chain defects. J Pediatr 121:940–942
Gibson KM, Elpeleg ON, Jakobs C, Costeff H, Kelley RI
(1993) Multiple syndromes of 3-methylglutaconic aciduria.
Pediatr Neurol 9:120–123
Gould SJ, Keller G-A, Hosken N, Wilkinson J, Subramani S
(1989) A conserved tripeptide sorts proteins to peroxisomes.
J Cell Biol 108:1657–1664
Holme E, Greter J, Jacobson CE, Larsson NG, Lindstedt S,
Nilsson KO, Oldfors A, Tulinius M (1992) Mitochondrial
ATP-synthase deficiency in a child with 3-methylglutaconic
aciduria. Pediatr Res 32:731–735
Ibel H, Endres W, Hadorn HB, Deufel T, Paetzke I, Duran M,
Kennaway NG, Gibson KM (1993) Multiple respiratory
chain abnormalities associated with hypertrophic cardiomy-
opathy and 3-methylglutaconic aciduria. Eur J Pediatr 152:
665–670
Kelley RI, Kratz L (1995) 3-Methylglutaconic acidemia in Smith-
Lemli-Opitz syndrome. Pediatr Res 37:671–674
Nystuen A, Costeff H, Elpeleg ON, Apter N, Bonne-Tamir B,
Mohrenweiser H, Haider N, Stone EM, Sheffield VC (1997)
Iraqi Jewish kindreds with optic atrophy plus (3-methylglu-
taconic aciduria type 3) demonstrate linkage disequilibrium
with the CTG repeat in the 3′ untranslated region of the
myotonic dystrophy protein kinase gene. Hum Mol Genet
6:563–569
Riordan-Eva P, Harding AE (1995) Leber’s hereditary optic
neuropathy: the clinical relevance of different mitochondrial
DNA mutations. J Med Genet 32:81–87
Scaglia F, Sutton VR, Bodamer OA, Vogel H, Shapira SK, Na-
viauxRK,VladutiuGD (2001)MitochondrialDNAdepletion
associated with partial complex II and IV deficiencies and 3-
methylglutaconic aciduria. J Child Neurol 16:136–138
Shapiro MB, Senepathy P (1987) RNA splice junctions of dif-
ferent classes of eukaryotes: sequence statistics and func-
tional implications in gene expression. Nucleic Acids Res
15:7155–7174
Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka
T, Stern C, Weiss E, Seligsohn U (1995) One of the two
common mutations causing factor XI deficiency in Ashke-
nazi Jews (type II) is also prevalent in Iraqi Jews, who rep-
resent the ancient gene pool of Jews. Blood 85:429–432
Stoffman N, Magal N, Shohat T, Lotan R, Koman S, Oron A,
1224 Am. J. Hum. Genet. 69:1218–1224, 2001
Danon Y, Halpern GJ, Lifshitz Y, Shohat M (2000) Higher
than expected carrier rates for familial Mediterranean fever
in various Jewish ethnic groups. Eur J Hum Genet 8:307–
310
Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B,
Wanders RJ, Barth PG (2000) Defective remodeling of cardio-
lipin and phosphatidylglycerol in Barth syndrome. Biochem
Biophys Res Commun 279:378–382
Wanders RJA, Ruiter J, Barth P, Wiburg F, Elpeleg O, Gibson
KM (1992) Mitochondrial oxidative phosphorylation in fi-
broblasts from 3-methylglutaconic aciduria patients. Paper
presented at the Annual Meeting of the Society for the Study
of Inborn Errors of Metabolism, September 10–12
Zlotogora J, Bach G, Munnich A (2000) Molecular basis of
Mendelian disorders among Jews. Mol Genet Metab 69:
169–180
